跳至主要内容
临床试验/NCT07526857
NCT07526857已完成不适用

Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy: A12 Month Multimodal Imaging Study

Federico II University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Epivascular glia regression

研究概览

简要总结

The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • diagnosis of diabetic macular edema, diabetic retinopathy

排除标准

  • previous ocular surgery, history of vitreoretinal and/or retinal vascular diseases, uveitis, myopia over 6 dioptres, significant corneal and/or lens opacity, glaucoma, ocular MNV related to other causes than nAMD, geographic atrophy, subretinal fibrosis, previous treatments for MNV

研究组 & 干预措施

Diabetic macular edema treated with Eylea 2 mg

Diabetic macular edema treated with Eylea 2 mg

干预措施: Aflibercept (2.0 mg) (Drug)

Diabetic macular edema treated with Faricimab

干预措施: Faricimab Injection [Vabysmo] (Drug)

结局指标

主要结局

Epivascular glia regression

时间窗: From January 2025 to January 2026

Epivascular glia regression

Macular pigment changes

时间窗: From January 2025 to January 2026

Macular pigment changes

次要结局

未报告次要终点

研究者

发起方
Federico II University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gilda Cennamo

GCennamo

Federico II University

研究点 (1)

Loading locations...

相似试验

Epivascular Glia Regression and Macular Pigment... | 临床试验